REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

Freelancers, social media creators, and anyone looking to make branding quickly and easily should check out Looka.

AI logo makers promise pro designs in minutes—but do they deliver? Compare the top free AI tools of 2025 & find out if AI can ...

Osaka is one of the busiest tourism hubs in Japan. In a recent report, Savills noted that Osaka attracted a record 14.6 ...

In the final quarter of 2024, new supply brought around 294,000 sqm of warehouse space to the Melbourne industrial market, 69 ...

The iconic badges of teams like Barcelona, Real Madrid, Manchester United, Liverpool and Arsenal are recognised around the ...

If you’d like to remember the days before X, Engadget points out that an auction for one of two large signs from the ...

This spoofed email will appear to the user to have come from simply “Co-pilot.” Users may have some familiarity with using Copilot to perform a myriad of tasks such as transcribing emails or drafting ...

The pandemic bared the cruelty of prison in new ways. It was a lost opportunity to move away from mass incarceration.

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.